All financings
COMPANY TRANSACTIONS

Alaunos Therapeutics, Inc.

TCRTNasdaqBiotechnology

Deal details

1 transaction in the database

TRANSACTION REPORT · SEC DISCLOSURES
Gross proceeds$1.1M
Offering price$1.46
Discount to prior close8.8%
Warrant coverage—
Placement agent / underwriterDawson James Securities, Inc.

Transaction overview

01

Alaunos Therapeutics, Inc. completed a $1.1M registered direct at $1.46 per share. Dawson James Securities, Inc. acted as placement agent for the financing.

Financing type
Registered Direct
Announcement date
Sep 18, 2026
Pricing date
Sep 18, 2026
Closing date
Sep 21, 2026
Filing date
Sep 22, 2026
Status
Closed
Market cap before announcement
$3.9M
Prior closing price
$1.60
Raise as % of market cap
28.8%

Market data · FMP

Historical market cap
$3,890,712
Market date
Sep 17, 2026
Closing price
$1.60
Latest reported shares outstanding
2,442,146
Latest reported float shares
1,866,481
Share-data date
Sep 30, 2026

Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Oct 1, 2026.

Financial Modeling Prep ↗

Financing terms

02

Equity

Common shares issued
380,469
Price per share
$1.46
Pre-funded warrants
386,654
Pre-financing shares disclosed in filing
—
Shares outstanding after financing
—

Fees & transaction economics

03
Placement agent / underwriting fee
8%
Agent fee amount
$89,600
Management fee
—
Other offering expenses (estimated)
—
Net proceeds (estimated)
$915,400.5
Net proceeds as % of gross
81.7%

Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.

Transaction participants

04
Investor names: —

Source documents

05

SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.

8-K · Alaunos Therapeutics, Inc.SEC filing · Sep 22, 2026
Open source ↗
EX-10.1 · Alaunos Therapeutics, Inc.SEC filing · Sep 22, 2026
Open source ↗
EX-10.2 · Alaunos Therapeutics, Inc.SEC filing · Sep 22, 2026
Open source ↗
EX-10.3 · Alaunos Therapeutics, Inc.SEC filing · Sep 22, 2026
Open source ↗
EX-4.1 · Alaunos Therapeutics, Inc.SEC filing · Sep 22, 2026
Open source ↗
EX-5.1 · Alaunos Therapeutics, Inc.SEC filing · Sep 22, 2026
Open source ↗
EX-99.1 · Alaunos Therapeutics, Inc.SEC filing · Sep 22, 2026
Open source ↗
FMP historical market data · TCRTMarket data · Sep 17, 2026
Open source ↗
SEC deal terms · FMP market data where available · Initial research sample, not complete market coverage. AI-assisted source review; original evidence is available in each report. Names and tickers reflect the transaction date. A dash (—) means the value is unavailable.